Skip to main content

Table 2 Measurements of lesions by mRECIST & vRECIST both before and after TACE and percentage of tumour change

From: Role of multislice computed tomography 3D volumetric analysis in the assessment of the therapeutic response of hepatocellular carcinoma after transarterial chemoembolization

  Mean Standard deviation Median Minimum Maximum
Pre mRECIST 5.36 3.06 4.80 1.50 13.60
Post mRECIST 3.98 2.62 3.32 .00 11.80
% (Tc) mRECIST .28 .25 .25 − .35- 1.00
Pre vRECIST 96.76 141.67 52.90 2.90 570.00
Post vRECIST 97.56 143.46 53.40 2.90 593.00
Viable post vRECIST 34.56 53.79 13.25 .00 292.00
% (Tc) vRECIST .66 .24 .69 − .24- 1.00